Though still a highly speculative equity, Stereotaxis (STXS) appears to be in a sweet spot for potential revenue growth and for becoming an acquisition target by larger companies that are in the fields of medical devices and/or robotics. Shares of STXS have had a volatile last several months, but have recently performed well and appear poised to continue doing so throughout 2014. See a recent performance chart (click to enlarge):
Stereotaxis is the market leader in robotic navigation solutions for the treatment of arrhythmias and coronary disease, with a portfolio of over 100 patents for use in hospital surgical suites. The company's key device uses magnets to generate a Tesla field in a patient's heart, and then uses...
Only subscribers can access this article, which is part of the PRO research library covering 3,553 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: